Author

F. Cunningham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

P. G. Wyatt· 2 shared A. Czarna· 1 shared A. Hope· 1 shared A. Karim· 1 shared A. Matsuda· 1 shared A. Plater· 1 shared B. Baragana· 1 shared B. Forte· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

P. G. Wyatt

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Quest to Identify USP8 Inhibitors for Parkinsons Disease, a PAINful Experience.

S. Lang, F. Bellany, D. Lin, D. S. Barrett, K. R. Cartmill, D. A. Fletcher, C. Kerr, A. Plater, B. Forte, B. Baragana, P. Dixit, M. M. Littleson, M. C. Wheldon, D. W. Gray, F. Cunningham

The paper identifies PAINS in a USP8 inhibitor screening campaign for Parkinson's disease and discusses interference mechanisms affecting assay reliability.

bioRxiv · Sep 5, 2023 · PreprintPharmacology & Toxicology

Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity.

A. Czarna, J. Plewka, L. Kresik, A. Matsuda, A. Karim, C. Robinson, S. O Byrne, F. Cunningham, I. Georgiou, M. Pachota, G. Popowicz, P. G. Wyatt, G. Dubin, K. Pyrc

The paper presents the crystal structure of SARS-CoV-2 nsp14 in apo-form and explains how nsp10 modulates its exonuclease activity through structural changes.

Structure · Aug 1, 2022Peer-reviewedMicrobiology

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

L. Armstrong, S. M. Lange, V. de Cesare, S. P. Matthews, R. S. Nirujogi, I. Cole, A. Hope, F. Cunningham, R. Toth, R. Mukherjee, D. Bojkova, F. Gruber, D. Gray, P. G. Wyatt, J. Cinatl, , Y. Kulathu

This study characterizes Nsp3 protease activity from SARS-CoV-2 and identifies nanobodies that inhibit PLpro with nanomolar affinity.

bioRxiv · Dec 9, 2020Biochemistry